Recently, BRCA1 and BRCA2 somatic mutations were detected in circulating free DNA of breast and ovarian tumors resistant to platinum-based therapy and to PARPi in patients with BRCA1 and BRCA2 germline mutations [62]. The gene discussed is BRCA1; the disease is ovarian neoplasm.